<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04956783</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0298</org_study_id>
    <nct_id>NCT04956783</nct_id>
  </id_info>
  <brief_title>Occurrence of Adverse Effects With Immune Checkpoint Inhibitors Between a Single and Double Dose Regimen</brief_title>
  <acronym>ICI DODO</acronym>
  <official_title>Comparison of the Occurrence of Adverse Effects With Immune Checkpoint Inhibitors Between a Single and Double Dose Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective evaluation of the impact of a double dose regimen of immunotherapy&#xD;
      use in cancer treatment compared to the single-dose regimen on the occurrence of clinically&#xD;
      significant adverse events.&#xD;
&#xD;
      The aim of this study is to provide evidence-based arguments to help clinicians to propose&#xD;
      the best treatment regimen for each patient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the incidence of clinical significant toxicities</measure>
    <time_frame>18 months</time_frame>
    <description>To compare the incidence of clinical significant toxicities reported for patients treated with a cancer immunotherapy on a simple dose regiment versus double dose regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe the incidence</measure>
    <time_frame>18 months</time_frame>
    <description>To describe the incidence, type and severity of overall toxicities (serious and non-serious) reported with single and double dose cancer immunotherapy regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify risk factors for the development of severe toxicity</measure>
    <time_frame>18 months</time_frame>
    <description>To identify risk factors for the development of severe toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the management and evolution of toxicities</measure>
    <time_frame>18 months</time_frame>
    <description>To describe the management and evolution of toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the clinical oncologic response</measure>
    <time_frame>18 months</time_frame>
    <description>To describe the clinical oncologic response</description>
  </secondary_outcome>
  <enrollment type="Actual">500</enrollment>
  <condition>Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Any adult patient (over the age of 18) from Montpellier University Hospital or Montpellier&#xD;
        Cancer Institute who has initiated an immunotherapy between 01/01/2019 and 31/12/2020 with&#xD;
        anti-PD-1 or PD-L-1 immune checkpoint inhibitor as monotherapy (nivolumab, pembrolizumab,&#xD;
        atezolizumab, durvalumab, avelumab)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        - Any adult patient with anti-PD-1 or PD-L-1 immune checkpoint inhibitor as monotherapy&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - age &lt; 18&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Maria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

